---

---

tags : Cancer    crawled time : 13:00   

save search

---

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ONCT | News | $8.79 -1.79% -1.82% 2.8K |

Health Technology

| Email alert Add to watchlist
onct-534 first cancer treatment for study

---

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
CVAC | News | $2.44 -5.06% -5.33% 710K |

Health Technology

| -7.92% | O: -0.38% H: 3.41% C: 0.95%
cancer collaboration

---

BostonGene and Saga University Announce Collaboration to Uncover Biomarkers for Improved Immunotherapy Response in Lung Cancer Patients
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
NIPNF | $68.91 -52.94% 120 |

Technology Services

| Email alert Add to watchlist
lung cancer immunotherapy for collaboration saga response biomarkers

---

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
ICCM | $1.24 -3.88% -4.03% 110K |

Manufacturing

| Email alert Add to watchlist
free breast cancer medical trial results

---

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
URGN | $14.32 0.56% 0.56% 320K |

Health Technology

| -5.1% | O: 1.46% H: 1.17% C: -1.44%
ugn-103 fda drug bladder cancer for application

---

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K |

Health Technology

| -6.19% | O: 4.76% H: 0.45% C: -5.91%
drug candidate liver cancer treat namodenoson advanced

---

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M |

Health Technology

| 1017.36% | O: 1842.45% H: 0.0% C: 0.0%
cancer

---

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Published: 2024-04-11 (Crawled : 13:00) - globenewswire.com
CADL | $5.49 0.92% 0.91% 740K |

| 7.06% | O: 25.49% H: 23.75% C: 13.75%
can-2409 fda drug cancer pancreatic treatment designation for therapeutics

---

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K |

Health Technology

| -2.97% | O: -2.97% H: 0.0% C: 0.0%
com503 cancer research immunology potential

---

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
BIAF | $2.78 -4.47% -4.68% 140K |

| -4.12% | O: -7.22% H: 0.0% C: -3.33%
lung initiative cancer for

---

Sanofi Agrees to Settle 4,000 Zantac Cancer Lawsuits in US State Courts
Published: 2024-04-04 (Crawled : 13:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -5.25% | O: 1.18% H: 0.0% C: 0.0%
state cancer sanofi

---

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M |

Health Technology

| -3.82% | O: 0.13% H: 0.0% C: 0.0%
cancer trial initiated

---

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
Published: 2024-04-01 (Crawled : 13:00) - globenewswire.com
CYCC | $1.86 -5.1% -5.38% 38K |

Health Technology

| -20.85% | O: 4.27% H: 0.0% C: -5.45%
precision asco cancer pharmaceuticals meeting potential

---

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Published: 2024-03-20 (Crawled : 13:00) - biospace.com/
PBYI | $4.98 -3.68% -3.82% 290K |

Health Technology

| 20.23% | O: 2.33% H: 7.73% C: 6.7%
fda breast cancer hormone

---

Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
Published: 2024-03-15 (Crawled : 13:00) - globenewswire.com
ONCT | News | $8.79 -1.79% -1.82% 2.8K |

Health Technology

| 14.45% | O: -4.32% H: 8.26% C: 7.19%
cancer treatment key

---

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Published: 2024-03-14 (Crawled : 13:00) - globenewswire.com
NVCT | $6.725 -0.52% -0.52% 81K |

| -29.88% | O: 22.93% H: 2.11% C: -22.78%
nxp800 pharma cancer trial

---

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
Published: 2024-03-11 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.5195 3.59% 3.46% 270K |

Professional, Scientific, and T...

| -28.47% | O: 2.86% H: 0.0% C: -11.14%
report genomics cancer treatment technology therapeutics

---

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-07 (Crawled : 13:00) - globenewswire.com
BCAB | $2.43 -3.95% -4.12% 360K |

| -7.57% | O: -1.06% H: 1.42% C: 1.07%
association cancer research meeting

---

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
Published: 2024-03-07 (Crawled : 13:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -11.54% | O: -0.64% H: 4.52% C: -6.45%
breast cancer

---

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
Published: 2024-03-07 (Crawled : 13:00) - globenewswire.com
PVCT | News 4 | $0.19 -15.0% 60K |

Manufacturing

| 11.76% | O: 0.59% H: 28.01% C: 24.68%
pv-10 cancer immunotherapy meeting

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---